samedan logo
home > ebr > summer 2021 > streamlining affinity analysis for accelerated lead screening, characterisation, optimisation, and final selection
European Biopharmaceutical Review

Streamlining Affinity Analysis for Accelerated Lead Screening, Characterisation, Optimisation, and Final Selection

Drug molecules are increasing in complexity, with bispecific and trispecific antibodies, fusion proteins, and antibody-drug conjugates (ADCs) gaining prominence within drug discovery programmes. Most analytical techniques are unable to measure sequential binding events to evaluate a single molecule’s specificity and affinity to multiple targets in one assay set up. That is an absolute requirement for these types of leads. With increasing complexity in the molecular library, along with an increase in the number of drug development programmes that are run in parallel, higher throughput affinity measurement methods are continuously sought to keep pace with specialised assay requirements for these drug candidates’ characterisation.

There are several challenges associated with generating reliable kinetic and affinity information about early candidates, also known as ‘hits’, at various stages of the lead selection process:

  1. Multiple instruments needed to run large screens all the way to high-quality characterisation rapidly to eliminate unsuitable candidates
  2. The ongoing increase in number and complexity of molecules with distinct assay requirements
  3. Reliably measuring affinity for lead candidates with slow off-rates and/or high affinities
  4. Sample consumption, especially during early stages of screening when sample quantities are low
  5. Need for expert operators

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Sartorius is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Lab Products & Services Division serves the needs of labs performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division, focusing on single-use solutions, helps customers to manufacture biotech medications and vaccines safely and efficiently. In 2020, the company earned sales revenue of some €2.34 billion. At the end of 2020, nearly 11,000 people were employed at the Group’s more than 50 manufacturing and sales sites, serving customers worldwide.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Owen Mumford Launches New 2-Step Single-Use Auto-Injector Platform Aidaptus®

OXFORD, England, 22nd September - Owen Mumford Pharmaceutical Services, a division of Owen Mumford Ltd. has launched its new Aidaptus® auto-injector platform following successful completion of development. Aidaptus is a 2-step, spring-powered, single use auto-injector with a versatile design that accommodates both 1mL and 2.25 mL prefilled glass syringes in the same base device. It also features stopper sensing technology with a self-adjusting plunger that automatically adapts to the individual stopper positions and different fill volumes in each syringe, with no change parts required. The auto-injector is available with two different spring strengths to accommodate a variety of drug viscosities.
More info >>

White Papers

Medpace Reference Laboratories establishes state of the art Flow Cytometry techniques for flexible approaches to clinical trials across multiple therapeutic areas.


Cytometry is the process of measuring the properties of individual cells. These properties may include gene or protein expression, chemical properties, deoxyribonucleic acid (DNA) content, and various cellular functions. The earliest methods of cytometry relied upon light microscopy for the classification and observation of cells and cellular components. Microscopy permitted direct visual observation of cells for the first time, leading to the classification of cells by morphology and insight into cellular functions. However, the time required for microscopic analysis constrains the number of samples or number of cells in each sample that can be examined. Therefore, the utility of microscopy for analysis of rare cells or in situations where sample throughput is a priority is limited. Flow cytometry was developed largely to improve upon these limitations.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement